ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Lenvatinib Plus Paclitaxel as Second-Line Therapy for Advanced Gastric Cancer Patients: A Dose Escalation Exploratory Study.

Chenfei Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.